ABUS vs CTVA · P/E 5.4, rev $6.2M vs P/E 42, rev $16.91B
Arbutus Biopharma Corp (ABUS) versus Corteva Inc (CTVA) — a side-by-side from cached financials, not a winner call.
Arbutus Biopharma Corp (ABUS) is a biotechnology company listed on NASDAQ.
Corteva Inc (CTVA) is a agricultural inputs company listed on US.
Latest reported ABUS revenue for 2024-12-31 was $6.2M. Net income was -$69.9M. Revenue was down 66.0% from 2023-12-31 to 2024-12-31. ABUS currently screens at market cap $883.0M and trailing P/E 5.4.
Latest reported CTVA revenue for 2024-12-31 was $16.91B. Net income was $919.0M. Revenue was down 1.8% from 2023-12-31 to 2024-12-31. CTVA currently screens at market cap $51.52B and trailing P/E 41.6.
ABUS currently screens at market cap $883.0M and trailing P/E 5.4. CTVA currently screens at market cap $51.52B and trailing P/E 41.6.
Not investment advice. Open the ABUS and CTVA stock pages for the full models.
Not investment advice.